Bei Akademie registrieren
Regeneron, US75886F1075

Regeneron stock, biopharmaceutical company, at EUR 730.60 pre-market

Published on 10/23/2026 at 07:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Regeneron lists its third-quarter 2026 earnings release for October 30, 2026. At Lang & Schwarz the stock trades pre-market at EUR 730.60 on October 23, 2026.

Calendar and business profile

  • Regeneron develops and sells medicines through research, development and pharmaceutical operations.
  • The company lists its third-quarter 2026 earnings release for October 30, 2026.
  • Regeneron stock trades pre-market at EUR 730.60 at 7:43 a.m. CEST at Lang & Schwarz on October 23, 2026.
Fotorealistisches Biotech-Labor mit Forschern und Pipetten an sterilen Arbeitsplätzen
Regeneron Pharma US75886F1075 zeigt ein fotorealistisches Biotech-Labor mit Forschern bei sorgfältigen Pipettierarbeiten am sterilen Steriltisch, Illustration mit AI erstellt.

Regeneron develops, produces and sells medicines through research and development in areas including ophthalmology, inflammatory diseases and cancer, according to MarketScreener. Regeneron stock trades pre-market at EUR 730.60 at 7:43 a.m. CEST at Lang & Schwarz on October 23, 2026.

Ahead of the Xetra open

The indication is before the Xetra session, which begins at 9:00 a.m. CEST. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Regeneron stock.

Business and scheduled results

Regeneron focuses on discovering, developing, manufacturing and selling pharmaceutical products. The company’s calendar lists a third-quarter 2026 earnings release for October 30, 2026, according to MarketScreener. Market context: Market report S&P 500.

More news and analysis on Regeneron stock

Disclaimer...
en | US75886F1075 | REGENERON | boerse | 70396597 | bgmi